The Nebraska Medical Association

https://www.nebmed.org/

 

Nebraska Oncology Society
G

2020 ASCO Highlights on Advanced CRC: Does mFOLFIRINOX Show DFS Benefit vs. Chemoradiation Among LARC Patients? Is Encorafenib+Cetuximab+/-Binimetinib Effective for BRAF V600E Mutations? What Is the ORR With T-DXd in HER2+ Metastatic Disease?

By Nebraska Oncology Society FEATURING George Kim
By Nebraska Oncology Society FEATURING George Kim
0 views
November 30, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Nebraska Oncology Society
07:33
Nebraska Oncology Society

Targeted Therapy for mNSCLC: What Is the Response Rate With Selperca…

Feat. G. Riely
15:24
Nebraska Oncology Society

NSCLC Targeted Therapies Update: Should We Consider EGFR Targeted Th…

Feat. G. Riely
09:41
Nebraska Oncology Society

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS …

Feat. E. Sherman
09:24
Nebraska Oncology Society

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDD…

Feat. E. Sherman
11:38
Nebraska Oncology Society

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMR…

Feat. E. Sherman
04:56
Nebraska Oncology Society

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy…

Feat. E. Sherman
08:09
Nebraska Oncology Society

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy…

Feat. E. Sherman
06:13
Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced UC: Is Atezo Benef…

Feat. N. Vogelzang
17:42
Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on PC: Does 18F-DCFPyL-PET/CT …

Feat. N. Vogelzang
13:26
Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced RCC: Is 1L Pembro+…

Feat. N. Vogelzang
11:59
Nebraska Oncology Society

2020 ASCO mCRC Updates Recap: Did We Experience Pseudoprogression Wi…

Feat. G. Kim
05:11
Nebraska Oncology Society

2020 ASCO Updates on GI Cancers: Is Chemo w/ mFOLFIRINOX More Effect…

Feat. G. Kim
10:06
Nebraska Oncology Society

2020 ASCO Highlights on Advanced CRC: Does mFOLFIRINOX Show DFS Bene…

Feat. G. Kim
04:13
Nebraska Oncology Society

2020 ASCO Updates on mCRC: Is Adjuvant mFOLFOX Superior to Hepatecto…

Feat. G. Kim
07:52
Nebraska Oncology Society

2020 ASCO Highlights on Stage 3 Colon Cancer: What Are the DFS/OS Di…

Feat. G. Kim
10:48
Nebraska Oncology Society

KEYNOTE-177 2020 ASCO Update on MSI-H/dMMR mCRC: Does Pembro Improve…

Feat. G. Kim
07:39
Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…

Feat. G. Riely
16:08
Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…

Feat. G. Riely
30:39
Nebraska Oncology Society

2020 ASCO Updates on IO in Advanced Melanoma: What Are the Outcomes …

Feat. S. Bhatia
10:23
Nebraska Oncology Society

2020 ASCO Highlights on Neoadjuvant IO in Stage 3 Melanoma: Does Ipi…

Feat. S. Bhatia
21:02
Nebraska Oncology Society

2020 ASCO Updates on Frontline Multiple Myeloma: KRd vs. VRd - What …

Feat. A. Cohen
25:01
Nebraska Oncology Society

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer …

Feat. A. Cohen